# Response to Emerging Antimicrobial Resistance With Containment Microbiota Therapy (REACT)

> **NCT06321536** · PHASE2 · RECRUITING · sponsor: **Emory University** · enrollment: 60 (estimated)

## Conditions studied

- Multi-Drug Resistant Organism Colonization

## Interventions

- **DRUG:** Allogeneic Microbiota in Glycerol (9%) (AMG)

## Key facts

- **NCT ID:** NCT06321536
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-13
- **Primary completion:** 2026-07
- **Final completion:** 2026-12
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-11-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06321536

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06321536, "Response to Emerging Antimicrobial Resistance With Containment Microbiota Therapy (REACT)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06321536. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*